乳癌市場 - 三陰性-KOL的洞察

本報告提供三陰性乳癌市場相關調查，現在及未來的治療流程，已上市及開發平台的治療藥趨勢等彙整資訊。

目錄

摘要整理

三陰性乳癌的現在及未來的治療流程

調查目的

三陰性乳癌

• 已上市藥物
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Talzenna (talazoparib; Pfizer)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
• 開發平台藥物
  • Bavencio (avelumab; Merck Group)
  • veliparib (ABT-888; AbbVie)
  • Zejula (niraparib; GlaxoSmithKline)
  • ipatasertib (Roche) and capivasertib (AstraZeneca)
  • Piqray (alpelisib; Novartis)
  • Cosela (trilaciclib; G1 Therapeutics)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
• 影響治療的一般未來趨勢
  • 重要的洞察概要

附錄

• KOL詳細內容
  • 北美的KOL
  • 歐洲的KOL

What's exciting oncologists in triple-negative cancer therapy? What clinical benefits do KOLs cite for AstraZeneca/Daiichi Sankyo's pipeline datopotamab deruxtecan and why will the readouts of the BEGONIA trial be significant? Why do experts believe the mechanism of action of G1 Therapeutics' late-stage CDK4/CDK6 inhibitor Cosela could lead to improved outcomes? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and KOL Bulletins via the attachments area.

Table of Contents

Executive summary

Triple-negative breast cancer current and future treatment algorithm

Research objectives

Triple-negative breast cancer

• Marketed drugs
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Talzenna (talazoparib; Pfizer)
  • Tecentriq (atezolizumab; Roche)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
• Pipeline drugs
  • Bavencio (avelumab; Merck Group)
  • veliparib (ABT-888; AbbVie)
  • Zejula (niraparib; GlaxoSmithKline)
  • ipatasertib (Roche) and capivasertib (AstraZeneca)
  • Piqray (alpelisib; Novartis)
  • Cosela (trilaciclib; G1 Therapeutics)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)
• General future trends impacting treatment
  • Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe